Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $9.29

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $9.29.

NMRA has been the subject of a number of research analyst reports. HC Wainwright cut their price objective on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Thursday, April 10th. William Blair lowered shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Finally, Bank of America reaffirmed an “underperform” rating and set a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NMRA. Geode Capital Management LLC lifted its stake in Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares during the last quarter. Barclays PLC raised its holdings in shares of Neumora Therapeutics by 352.9% in the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock worth $1,708,000 after buying an additional 100,678 shares during the period. Swiss National Bank bought a new stake in shares of Neumora Therapeutics during the fourth quarter worth $1,168,000. State Street Corp lifted its holdings in Neumora Therapeutics by 65.3% during the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after buying an additional 707,409 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $143,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Up 2.7 %

NASDAQ:NMRA opened at $0.65 on Friday. The business’s 50-day simple moving average is $1.20 and its two-hundred day simple moving average is $6.24. Neumora Therapeutics has a 52 week low of $0.62 and a 52 week high of $17.19. The stock has a market cap of $104.77 million, a PE ratio of -0.35 and a beta of 2.89.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Sell-side analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.